Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists-Reference-Cited by-同舟云学术

Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists

Published:2017-09-19 Issue:5 Volume:31 Page:447-459
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

van Overbeeke Eline^ORCID,De Beleyr Birgit,de Hoon Jan,Westhovens Rene,Huys Isabelle

Funder

This work was not financially supported by any funding agency or grant

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/article/10.1007/s40259-017-0244-3/fulltext.html

Reference47 articles.

1. Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10(8):981–3.

2. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology” “O brave new world”. Nat Rev Rheumatol. 2012;8(7):430–6.

3. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. European Medicines Agency. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf . Accessed 18 Apr 2017.

4. Jha D, Mishra RK, Pandey R. Biosimilars: current regulatory perspective and challenges. J Pharm Bioallied Sci. 2013;5(1):80–1.

5. The European Parliament and of the Council. Art. 10(4) of the directive 2001/83/EC on the Community code relating to medicinal products for human use. 2001. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf . Accessed 18 Apr 2017.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obstacles to Biosimilar Acceptance and Uptake in Oncology;JAMA Oncology;2024-07-01

2. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12

3. An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage;Irish Journal of Medical Science (1971 -);2024-01-09

4. Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna;European Journal of Clinical Pharmacology;2023-12-22

5. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23